Navigation Links
BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins

Accentia Biopharmaceuticals, Inc. report follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients.

The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50% chance of surviving 3 years and 20% chance of surviving 5 years. BiovaxID, an investigational personalized anti-cancer vaccine, stimulates the immune system to seek out and destroy tumor cells. The data were published in a recent edition of Nature Medicine (Nat Med.2005; 11(9):986-91).

In this single-arm, open-label Phase 2 clinical study, patients with untreated mantle cell non-Hodgkin's lymphoma (NHL) were administered six cycles of dose-adjusted EPOCH-R, a chemotherapy regimen that includes Rituxan® (rituximab). Of the 26 patients in the study, 23 received vaccinations with BiovaxID commencing at least three months after completing their last chemotherapy and Rituxan treatments. Upon the 46-month (3.8-year) follow-up, the overall survival rate was 89%. This study showed that, despite an almost complete depletion of normal B-cell lymphocytes due to EPOCH-R therapy, BiovaxID did induce anti-tumor T-cell lymphocyte responses in most patients. Depletion of normal B-cell lymphocytes is a consequence of the combination of chemotherapy and Rituxan, but not of BiovaxID therapy. Thus, "it is justifiable to administer vaccines in the setting of B-cell depletion, but vaccine boosts after B-cell recovery may be necessary for optimal humoral responses," concluded the investigators.

Lymphocytes are a type of white blood cell. There are two types of lymphocytes: B-cell lymphocytes, which produce antibodies ("humoral" immunity) in response to immune stimulation; and T-cell lymphocytes, which mediate cell responses to immune stimulation ("cellular" immunity). B-cell lymphocytes can undergo malignant transformation to become non-Hogkins
'"/>

Source:The Investor Relations Group


Page: 1 2

Related biology news :

1. Hunger in America rises by 43 percent over last five years
2. Method slashes quantum dot costs by 80 percent
3. Hepatitis B accounts for 40 percent of missing Asian women
4. Vaccine provides 100 percent protection against avian flu virus in animal study
5. Oceans are 70 percent shark free
6. St. Jude projects 90 percent cure rate for ALL
7. Biofuels can replace about 30 percent of fuel needs with significant research and policy effort
8. Psychotropic drug prescriptions for teens surge 250 percent over 7 year period
9. Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent
10. Septum keeps neurons in synch, can reduce epileptic seizures by 90 percent
11. One therapeutic dose of radiation causes 30 percent spongy bone loss in mice
Post Your Comments:
(Date:8/27/2014)... to Europe based upon a proxy for impact have ... ,big data, approach to scientific research. , The researchers ... ranked the top 100 pathogens affecting humans and the ... they believe, will help governments across the continent plan ... including as a result of climate change, and for ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... York, NY (June, 2014) Outstanding basic research, ... and a dedication to patient care have earned ... Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital ... from the National Cancer Institute (NCI). The grant ... two NCI-designated Comprehensive Cancer Centers in New York ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... has named its awardee for this year,s Alan ... Brown University. Dunn,s work involves genome analyses ... He investigates the origins of biological complexity ... research holds clues about how complex multicellular organisms, ...
... This release is available in French . ... without exposing the healthy surrounding tissue to the medication,s toxic ... medical reality, thanks to the work of Professor Sylvain Martel, ... Known for being the world,s first researcher to have guided ...
... most controversial aspects in the sustainable management of golf courses. ... the practices relating to reclaimed water at one of the ... on the course receive 83% more water than they need. ... be justified from any perspective", Mara del Pino Palacios Daz, ...
Cached Biology News:Casey Dunn to receive NSF Waterman Award 2Casey Dunn to receive NSF Waterman Award 3World first -- Localized delivery of an anti-cancer drug by remote-controlled microcarriers 2Golf courses that reuse water irrigate too much 2Golf courses that reuse water irrigate too much 3
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 Guggenheim ... Guggenheim Partners, today announced the hiring of veteran equity ... senior equity analyst. Mr. Butler will focus on the ... our team a wealth of experience and a broad ... Ferrarie , Senior Managing Director and Head of Equities ...
(Date:8/27/2014)...  ARCH Venture Partners, one of the largest ... of seed and early-stage advanced technology companies, today ... more than $400 million in subscriptions. ARCH Venture ... by more than $150 million. "The ... potential of our approach to finding and funding ...
(Date:8/27/2014)... White City, OR (PRWEB) August 27, 2014 ... Supply Report, “Consolidation continues to reshape the look and ... in nutrition. Consumer demand for higher-quality ingredients will push ... the North American market have experienced strong market growth ... and ethical attributes in their food and cosmetics to ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... Distributor in Greece, to Purchase an Aggregate ... of Over $200,000 of Resurgex(R) in 2008, ... wholly owned subsidiary of Millennium,Biotechnologies Group, Inc. (OTC Bulletin Board: ... order for the international,distribution of the Resurgex(R) line in Greece. ...
... CAMBRIDGE, Mass., April 1, 2008 Abt ... Abt Bio-Pharma Solutions, Inc., a,wholly owned subsidiary of ... custom strategic, research and communication solutions for the,pharmaceutical, ... approach that blends decades of experience with wide,ranging ...
... MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... global biopharmaceutical company,focused on endocrine therapy and ... leading Canadian specialty pharmaceutical company, announced today,that, ... transactions under their,previously announced purchase and sale ...
Cached Biology Technology:Millennium Announces $200,000 Purchase Order From Greek Distributor 2Millennium Announces $200,000 Purchase Order From Greek Distributor 3Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 3
Yersinia pestis...
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: